This week’s Manufacturing Minute highlights CMTA members leading the way with major investments and advancements in workforce development, U.S. manufacturing, and pharmaceutical innovation.
Caterpillar Inc. Pledges $100M to Upskill Workforce for the AI Era
Caterpillar Inc., a leader in construction and mining equipment, is committing $100 million over the next five years to upskill its workforce in response to rapid technological advancements. With the global labor market evolving, particularly due to robotics, automation, and artificial intelligence (AI), Caterpillar plans to train workers in these critical areas, including digital twins and machine learning models. This initiative is part of the company’s broader effort to address the manufacturing skills gap and prepare its workforce for the demands of the future, which will include a greater need for both technology-related skills and human-centered skills like leadership and social influence.
Johnson & Johnson Increases U.S. Investment to More Than $55B
In other news, Johnson & Johnson has announced a significant increase in its U.S. investments, pledging more than $55 billion over the next four years. This investment, which includes plans to break ground on a $2 billion facility in North Carolina, aims to expand the company’s manufacturing, research, and development capabilities. The funds will support the creation of four new advanced manufacturing facilities, as well as the expansion of existing sites, which will generate thousands of high-paying jobs. Additionally, Johnson & Johnson is focusing on investments in R&D to develop life-saving treatments in critical areas such as oncology, immunology, and robotic surgery, further solidifying its commitment to American innovation and manufacturing.
Novartis Plans to Invest $23B in U.S. Manufacturing
Meanwhile, pharmaceutical giant Novartis is making a $23 billion commitment to build and expand 10 manufacturing and R&D facilities in the U.S. over the next five years. In response to renewed drug tariff threats from the Trump administration, Novartis will invest in new manufacturing plants, including some for producing raw pharmaceutical ingredients, and a new R&D center in San Diego, California. This investment will create more than 5,000 jobs, including positions for engineers, scientists, and support staff. The expansion highlights Novartis’ commitment to the U.S. market while also addressing the challenges posed by potential drug import duties, demonstrating a continued push to bolster its manufacturing presence in the country.
Stay up to date with all manufacturing news by following CMTA on social media.